Latest News

Moderna expects to make mFlusiva available in the U.S. ahead of the 2026-2027 respiratory virus season.

Alteogen designed Hybrozyme to help convert biologic medicines that are traditionally administered through intravenous infusion into subcutaneous formulations.

The Centre operates through the SHA 922 Lifeline and will coordinate ambulance deployment, emergency communications, patient referrals and links between emergency responders and health facilities.

Novo Nordisk will also use H1’s technology to support several aspects of clinical research, including trial design, patient enrollment and clinical trial site selection.

The newly raised capital will enable Inocras to expand its commercial operations and clinical infrastructure across the United States.

The company’s scientific capabilities include chimeric antigen receptor T-cell (CAR-T) therapies and treatments derived from induced pluripotent stem cells (iPSCs).

The companies will work together to generate pharmacological and bioanalytical data needed to advance NB4168 toward clinical development.

Both programmes will combine SOPHiA GENETICS’ decentralised clinical trial assay capabilities with AstraZeneca’s oncology therapies.

SMT’s adoption of Teamcenter is intended to improve visibility into product development activities while helping the company manage the documentation and controls required in the highly regulated medical device industry.

The company has launched Invenia Automated Breast Ultrasound (ABUS) Prime and ABUS StreamVue, which target different stages of the breast imaging workflow.